orphenadrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1999 83-98-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • disipal
  • orphenadrine
  • orphenadine
  • orphenadrin
  • orphenadrine citrate
  • orphenadrine hydrochloride
  • orphenadrine (chloride)
  • orphenadrine HCl
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
  • Molecular weight: 269.39
  • Formula: C18H23NO
  • CLOGP: 3.90
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -3.95
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.12 g O
0.12 g P
0.20 g O
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.21 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
May 10, 1957 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia viral 465.45 30.91 111 4535 6723 50593755
Soft tissue disorder 342.26 30.91 79 4567 4135 50596343
Herpes zoster 282.84 30.91 135 4511 70651 50529827
Oral pain 224.93 30.91 85 4561 24948 50575530
Fibromyalgia 217.44 30.91 98 4548 44880 50555598
Blood cholesterol increased 198.26 30.91 98 4548 55117 50545361
Liver function test abnormal 193.51 30.91 90 4556 44249 50556229
Leukopenia 179.64 30.91 98 4548 67430 50533048
Peripheral swelling 162.84 30.91 141 4505 205795 50394683
Arthritis 151.81 30.91 96 4550 86625 50513853
Synovitis 120.94 30.91 96 4550 123769 50476709
Infection 86.13 30.91 92 4554 172862 50427616
Libido increased 83.48 30.91 20 4626 1223 50599255
Soft tissue injury 79.96 30.91 20 4626 1464 50599014
Hostility 76.33 30.91 20 4626 1762 50598716
Post-traumatic neck syndrome 74.95 30.91 20 4626 1890 50598588
Sternal fracture 74.02 30.91 20 4626 1982 50598496
Tenderness 72.60 30.91 35 4611 18530 50581948
Anaemia 68.54 30.91 99 4547 252357 50348121
Joint swelling 61.95 30.91 93 4553 245193 50355285
Therapeutic product effect incomplete 60.79 30.91 57 4589 91458 50509020
Personality disorder 58.83 30.91 20 4626 4304 50596174
Nightmare 55.94 30.91 28 4618 16058 50584420
Muscle twitching 45.39 30.91 24 4622 15407 50585071
Middle insomnia 42.73 30.91 20 4626 9901 50590577
Soft tissue swelling 42.02 30.91 11 4635 965 50599513
Concussion 41.17 30.91 18 4628 7610 50592868
Oculogyric crisis 37.80 30.91 11 4635 1426 50599052
Poor quality sleep 33.00 30.91 20 4626 16626 50583852
Rib fracture 32.81 30.91 21 4625 19200 50581278

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Convulsive threshold lowered 32.88 31.07 6 539 497 29573485

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia viral 314.51 29.95 77 3917 7745 64486993
Soft tissue disorder 209.41 29.95 47 3947 3229 64491509
Fibromyalgia 154.04 29.95 64 3930 35667 64459071
Herpes zoster 143.38 29.95 78 3916 79109 64415629
Oral pain 124.40 29.95 51 3943 27442 64467296
Blood cholesterol increased 121.28 29.95 60 3934 50006 64444732
Liver function test abnormal 97.78 29.95 55 3939 59346 64435392
Arthritis 97.38 29.95 62 3932 83752 64410986
Leukopenia 93.72 29.95 65 3929 101177 64393561
Peripheral swelling 88.53 29.95 85 3909 209068 64285670
Soft tissue injury 86.56 29.95 20 3974 1559 64493179
Libido increased 84.07 29.95 20 3974 1770 64492968
Synovitis 83.31 29.95 60 3934 99030 64395708
Post-traumatic neck syndrome 82.86 29.95 20 3974 1882 64492856
Hostility 79.91 29.95 20 3974 2187 64492551
Sternal fracture 79.55 29.95 20 3974 2227 64492511
Tenderness 70.77 29.95 31 3963 19571 64475167
Therapeutic product effect incomplete 69.94 29.95 55 3939 103427 64391311
Personality disorder 64.89 29.95 20 3974 4691 64490047
Nightmare 56.29 29.95 27 3967 20966 64473772
Infection 47.83 29.95 58 3936 184822 64309916
Concussion 47.34 29.95 18 3976 7920 64486818
Middle insomnia 45.29 29.95 20 3974 12857 64481881
Sedation 41.55 29.95 28 3966 41434 64453304
Joint swelling 40.84 29.95 58 3936 215324 64279414
Soft tissue swelling 39.95 29.95 10 3984 1092 64493646
Poor quality sleep 37.93 29.95 20 3974 18931 64475807
Muscle twitching 37.89 29.95 20 3974 18978 64475760
Rib fracture 36.12 29.95 21 3973 24017 64470721
Anxiety 36.11 29.95 53 3941 202596 64292142
Oculogyric crisis 35.90 29.95 11 3983 2527 64492211
C-reactive protein abnormal 34.94 29.95 22 3972 29025 64465713
Arthralgia 33.50 29.95 80 3914 442180 64052558
Body temperature increased 30.28 29.95 22 3972 36644 64458094

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03BC01 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Ethers, chemically close to antihistamines
ATC M03BC51 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Ethers, chemically close to antihistamines
ATC N04AB02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
ANTICHOLINERGIC AGENTS
Ethers chemically close to antihistamines
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D065686 Cytochrome P-450 CYP2B6 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50370 parasympatholytics
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:60643 N-methyl-D-aspartate receptor antagonists
CHEBI has role CHEBI:66956 antidyskinetic agent
FDA PE N0000175730 Centrally-mediated Muscle Relaxation
FDA EPC N0000175737 Muscle Relaxant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinsonism indication 32798002
Spasticity indication 221360009
Necrotizing enterocolitis in fetus OR newborn contraindication 2707005
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Glaucoma contraindication 23986001 DOID:1686
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Poisoning by acetaminophen contraindication 70273001
Agoraphobia contraindication 70691001 DOID:593
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Myasthenia gravis contraindication 91637004 DOID:437
Obstruction of duodenum contraindication 95532008 DOID:3558
Anemia due to enzyme deficiency contraindication 111577008
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Obsessive-compulsive disorder contraindication 191736004 DOID:10933
Insomnia contraindication 193462001
Decompensated cardiac failure contraindication 195111005
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Panic disorder contraindication 371631005 DOID:594
Breastfeeding (mother) contraindication 413712001
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Acute erosive gastritis contraindication 444926003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 9 subunit alpha Ion channel BLOCKER IC50 4.76 WOMBAT-PK CHEMBL
Histamine H1 receptor GPCR ANTAGONIST Ki 7.96 WOMBAT-PK CHEMBL
Sodium channel protein type 10 subunit alpha Ion channel BLOCKER IC50 5.20 WOMBAT-PK CHEMBL
Sodium channel protein type 1 subunit alpha Ion channel BLOCKER IC50 4.89 WOMBAT-PK CHEMBL
Sodium channel protein type 4 subunit alpha Ion channel BLOCKER Ki 5.66 WOMBAT-PK CHEMBL
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 4.89 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 5.67 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.55 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.28 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.06 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.17 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.39 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 6.87 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.43 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.77 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.70 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.40 DRUG MATRIX
Solute carrier family 22 member 1 Transporter IC50 4.90 CHEMBL
Glutamate [NMDA] receptor Ion channel Ki 5.22 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.09 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.17 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 6.61 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 5.58 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.90 DRUG MATRIX
Histamine H1 receptor GPCR IC50 6.79 CHEMBL

External reference:

IDSource
4019866 VUID
N0000147952 NUI
D00774 KEGG_DRUG
4682-36-4 SECONDARY_CAS_RN
341-69-5 SECONDARY_CAS_RN
4018819 VANDF
4018820 VANDF
4019866 VANDF
C0029309 UMLSCUI
CHEBI:7789 CHEBI
CHEMBL900 ChEMBL_ID
CHEMBL1201023 ChEMBL_ID
DB01173 DRUGBANK_ID
CHEMBL1200395 ChEMBL_ID
D009966 MESH_DESCRIPTOR_UI
4601 PUBCHEM_CID
7251 IUPHAR_LIGAND_ID
658 INN_ID
AL805O9OG9 UNII
155039 RXNORM
4456 MMSL
5206 MMSL
d00966 MMSL
001648 NDDF
001649 NDDF
001650 NDDF
35035001 SNOMEDCT_US
372714007 SNOMEDCT_US
387167001 SNOMEDCT_US
395813009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0115-2011 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 10 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0022 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 13 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3222 INJECTION 30 mg INTRAMUSCULAR ANDA 11 sections
Orphenadrine citrate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6182 INJECTION 60 mg INTRAMUSCULAR ANDA 15 sections
Orphenadrine citrate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6182 INJECTION 60 mg INTRAMUSCULAR ANDA 15 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 10544-283 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 12 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-177 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 9 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 17478-538 INJECTION 30 mg INTRAMUSCULAR ANDA 15 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 21695-099 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 16 sections
Orphenadrine Citrate, Aspirin and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 21695-726 TABLET, MULTILAYER 50 mg ORAL ANDA 12 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 33261-088 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 16 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 33358-274 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 12 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 42549-559 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 11 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 43063-407 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 43063-407 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 43386-480 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 45865-363 TABLET 100 mg ORAL ANDA 13 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 49999-046 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 16 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0169 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-2438 INJECTION 30 mg INTRAMUSCULAR ANDA 14 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-3150 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
Orphenadrine Citrate Aspirin Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 50564-554 TABLET 25 mg ORAL ANDA 10 sections
Orphenadrine Citrate Aspirin Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 50564-555 TABLET 50 mg ORAL ANDA 10 sections
Norgesic Forte HUMAN PRESCRIPTION DRUG LABEL 3 50991-999 TABLET, MULTILAYER 50 mg ORAL ANDA 12 sections
Norgesic Forte HUMAN PRESCRIPTION DRUG LABEL 3 50991-999 TABLET, MULTILAYER 50 mg ORAL ANDA 12 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 52959-527 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 13 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 53002-5430 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
ORPHENADRINE CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 54868-4102 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 16 sections
Orphenadrine Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60760-810 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 12 sections
ORPHENGESIC FORTE HUMAN PRESCRIPTION DRUG LABEL 3 61825-302 TABLET 50 mg ORAL ANDA 11 sections